Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multicenter beta-blocker trials: certainties.

J Lubsen

    European Heart Journal
    |July 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Therapeutic evaluation relies on comparing treated versus untreated groups. Rigorous study designs, including randomization and placebo controls, ensure reliable results for treatments like beta-blockers post-myocardial infarction.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A Mechanized Pediatric Elbow Joint Powered by a De-Based Artificial Skeletal Muscle.

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2020
    Same author

    Survival analysis in total joint replacement: an alternative method of accounting for the presence of competing risk.

    The Journal of bone and joint surgery. British volume·2010
    Same author

    Treatment of angina pectoris: associations with symptom severity.

    International journal of cardiology·2005
    Same author

    Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses.

    Statistics in medicine·2000
    Same author

    Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained.

    Lancet (London, England)·2000
    Same author

    Heart failure treatments: issues of safety versus issues of quality of life.

    Drug safety·1999
    Same journal

    Impactful trials on dyslipidaemias, fractional flow reserve, beta-blockers, and peripheral artery disease.

    European heart journal·2026
    Same journal

    Correction to: The Safe Hearts Plan for Europe and beyond.

    European heart journal·2026
    Same journal

    AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

    European heart journal·2026
    Same journal

    Unrepaired persistent truncus arteriosus in adulthood: a rare survival explained by anatomy and flow.

    European heart journal·2026
    Same journal

    Biomarkers in cancer thrombosis: from association to mechanism and integrated risk.

    European heart journal·2026
    Same journal

    Weight loss, exercise haemodynamics, and health status with incretin therapy for heart failure with preserved ejection fraction and obesity.

    European heart journal·2026
    See all related articles

    Area of Science:

    • Clinical Trials Methodology
    • Cardiovascular Research
    • Pharmacological Studies

    Background:

    • Therapeutic evaluation typically compares treated and untreated groups.
    • Study design is critical for valid treatment outcome inferences.
    • Post-myocardial infarction patient trials are a key area for therapeutic evaluation.

    Purpose of the Study:

    • To highlight the importance of robust study design in therapeutic evaluation.
    • To underscore the benefits of specific methodological features in clinical trials.
    • To explain how design elements enhance confidence in trial results, particularly for beta-blocker trials.

    Main Methods:

    • Randomized treatment allocation to prevent selection bias and enable significance testing.
    • Use of placebo in a double-blind manner for comparability and interpretable results.

    Related Experiment Videos

  • Multicenter cooperation to enhance data representativeness and consistency checks.

    • Main Results:

    • Randomization ensures unbiased group formation and interpretable statistical significance.
    • Double-blind placebo controls allow for clear interpretation of drug effects versus concomitant medication.
    • Multicenter trials improve generalizability and allow for cross-validation of findings.

    Conclusions:

    • Methodological rigor, including randomization, blinding, and multicenter collaboration, is essential for valid therapeutic evaluations.
    • These design features increase confidence in the results of clinical trials, such as those for beta-blockers in post-myocardial infarction patients.
    • Ensuring comparability and minimizing bias are paramount for drawing accurate conclusions about treatment efficacy.